31.38
price down icon2.02%   -0.3586
 
loading

Vera Therapeutics Inc (VERA) 最新ニュース

pulisher
09:18 AM

Vera Therapeutics Enters $500M Credit Facility As It Nears FDA Filing For Kidney Disease Drug: Retail Sees Stock Touching $40 By Stocktwits - Investing.com India

09:18 AM
pulisher
07:01 AM

Vera Therapeutics Secures $500M Loan Agreement - TipRanks

07:01 AM
pulisher
06:32 AM

Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans - GlobeNewswire

06:32 AM
pulisher
06:31 AM

Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 ... - Bluefield Daily Telegraph

06:31 AM
pulisher
06:30 AM

Vera Therapeutics Lands Massive $500M Financing Deal as FDA Filing for Kidney Drug Approaches - Stock Titan

06:30 AM
pulisher
02:27 AM

Why Vera Therapeutics, Inc. (VERA) Skyrocketed On Monday - Yahoo

02:27 AM
pulisher
01:21 AM

These 10 Stocks Blew Past Expectations - Insider Monkey

01:21 AM
pulisher
Jun 02, 2025

Vera Therapeutics: Primary endpoint was met in ORIGIN Phase 3 trial of atacicept - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

H.C. Wainwright ups Vera Therapeutics target on ‘home run’ data - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

Buy Rating for Vera Therapeutics: Promising Potential of Atacicept in IgA Nephropathy Treatment - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

Arthur He CFA Upgrades Vera Therapeutics on Promising Phase 3 Results for Atacicept in IgAN Treatment - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

Vera’s Atacicept Sets A New Efficacy Bar With Phase III Results In IgAN - insights.citeline.com

Jun 02, 2025
pulisher
Jun 02, 2025

Vera Therapeutics (VERA) Surges 67.49% After Landmark Phase 3 Trial Results - Wealth Daily

Jun 02, 2025
pulisher
Jun 02, 2025

Evercore ISI maintains outperform rating on Vera Therapeutics stock By Investing.com - Investing.com South Africa

Jun 02, 2025
pulisher
Jun 02, 2025

Scotiabank Maintains Sector Outperform Rating for Vera Therapeutics (VERA) | VERA Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Vera rises after success in late-stage trial for IgA nephropathy treatment - Seeking Alpha

Jun 02, 2025
pulisher
Jun 02, 2025

Wedbush Raises Price Target on Vera Therapeutics to $32 From $26, Maintains Neutral Rating - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga

Jun 02, 2025
pulisher
Jun 02, 2025

Vera Therapeutics, Inc. Announces Atacicept Achieves 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Vera Therapeutics Reports Positive Phase 3 Results for Atacicept in IgA Nephropathy Treatment - geneonline.com

Jun 02, 2025
pulisher
Jun 02, 2025

Scotiabank Adjusts Price Target on Vera Therapeutics to $65 From $55, Maintains Outperform Rating - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Vera Therapeutics Says Trial of Kidney Disease Drug Achieves Primary Endpoint; Shares Jump - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

JPMorgan reiterates Vera Therapeutics stock rating after study data By Investing.com - Investing.com South Africa

Jun 02, 2025
pulisher
Jun 02, 2025

TD Cowen maintains buy rating for Vera Therapeutics stock - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

JPMorgan reiterates Vera Therapeutics stock rating after study data - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

Transcript : Vera Therapeutics, Inc.Special Call - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

VERA: HC Wainwright & Co. Raises Price Target for Vera Therapeutics | VERA Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Kidney Health-Focused Vera Therapeutics Stock Price Spikes On Heels Of Successful Trial Data - Benzinga

Jun 02, 2025
pulisher
Jun 02, 2025

Vera Therapeutics (VERA) Target Price Boosted Following Promising Study Results | VERA Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Pre-market Movers: LYRA, INM, OGEN, VERA... - RTTNews

Jun 02, 2025
pulisher
Jun 02, 2025

Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction In ORIGIN Phase 3 Trial In Adults With IgA Nephropathy - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Vera Therapeutics Reports Atacicept Reduces Toxic Protein Levels in IgA Nephropathy Trial - geneonline.com

Jun 02, 2025
pulisher
Jun 02, 2025

Vera Therapeutics shares soar on positive Phase 3 trial results By Investing.com - Investing.com Canada

Jun 02, 2025
pulisher
Jun 02, 2025

Vera Therapeutics shares soar on positive Phase 3 trial results - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

VERA's Phase 3 Trial of Atacicept Shows Promising Results in IgA - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Vera Therapeutics Announces Positive Phase 3 Trial Results - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

Why Vera Therapeutics Is Rising In Pre-market? - Nasdaq

Jun 02, 2025
pulisher
Jun 02, 2025

Vera Therapeutics Reports Positive Results from ORIGIN Phase 3 Trial of Atacicept for IgA Nephropathy, Meeting Primary Endpoint - Nasdaq

Jun 02, 2025
pulisher
Jun 02, 2025

Vera Therapeutics reports positive results from trial of kidney disease drug - statnews.com

Jun 02, 2025
pulisher
Jun 02, 2025

Vera Therapeutics Announces Atacicept Achieved 46% - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Breakthrough: New Drug Cuts Kidney Disease Protein by 46% in Phase 3 TrialFDA Filing Next - Stock Titan

Jun 02, 2025
pulisher
Jun 01, 2025

Ameriprise Financial Inc. Raises Stake in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World

Jun 01, 2025
pulisher
May 31, 2025

Millennium Management LLC Trims Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World

May 31, 2025
pulisher
May 29, 2025

Cantor Fitzgerald maintains $100 target on Vera Therapeutics stock By Investing.com - Investing.com Nigeria

May 29, 2025
pulisher
May 29, 2025

Cantor Fitzgerald maintains $100 target on Vera Therapeutics stock - Investing.com Australia

May 29, 2025
pulisher
May 26, 2025

Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Rating of “Buy” by Analysts - Defense World

May 26, 2025
pulisher
May 24, 2025

Cantor Fitzgerald maintains Vera Therapeutics at Overweight By Investing.com - Investing.com Canada

May 24, 2025
pulisher
May 24, 2025

Cantor Fitzgerald maintains Vera Therapeutics at Overweight - Investing.com

May 24, 2025
pulisher
May 23, 2025

Buy Rating for Vera Therapeutics Driven by Promising Phase III Results and Market Potential - TipRanks

May 23, 2025
pulisher
May 21, 2025

BNP Paribas Financial Markets Purchases Shares of 24,374 Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World

May 21, 2025
pulisher
May 19, 2025

Vera Therapeutics Holds 2025 Annual Stockholder Meeting - TipRanks

May 19, 2025
pulisher
May 17, 2025

Dimensional Fund Advisors LP Trims Position in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World

May 17, 2025
pulisher
May 15, 2025

Vera Therapeutics: Huge Catalyst Upcoming For Kidney Disease Drug (NASDAQ:VERA) - Seeking Alpha

May 15, 2025
pulisher
May 15, 2025

How To Trade (VERA) - news.stocktradersdaily.com

May 15, 2025
pulisher
May 15, 2025

Research Analysts Set Expectations for VERA FY2025 Earnings - Defense World

May 15, 2025
pulisher
May 14, 2025

Northern Trust Corp Has $19.24 Million Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World

May 14, 2025
pulisher
May 13, 2025

IgA Nephropathy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences, Shanghai Alebund Pharmaceuticals - The Globe and Mail

May 13, 2025
pulisher
May 11, 2025

FY2025 EPS Estimates for VERA Decreased by Cantor Fitzgerald - Defense World

May 11, 2025
pulisher
May 10, 2025

Q2 EPS Forecast for Vera Therapeutics Reduced by Analyst - Defense World

May 10, 2025
pulisher
May 10, 2025

Q2 EPS Estimates for Vera Therapeutics Boosted by Wedbush - Defense World

May 10, 2025
pulisher
May 10, 2025

Hsbc Holdings PLC Takes $264,000 Position in Vera Therapeutics, Inc. (NASDAQ:VERA) - The AM Reporter

May 10, 2025
pulisher
May 10, 2025

Cantor Fitzgerald Cuts Vera Therapeutics (NASDAQ:VERA) Price Target to $100.00 - Defense World

May 10, 2025
pulisher
May 10, 2025

Wedbush Cuts Vera Therapeutics (NASDAQ:VERA) Price Target to $26.00 - Defense World

May 10, 2025
pulisher
May 09, 2025

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 09, 2025
pulisher
May 09, 2025

What is Wedbush’s Estimate for VERA Q1 Earnings? - Defense World

May 09, 2025
$1.141
price up icon 0.00%
$30.62
price up icon 2.65%
$572.12
price down icon 2.46%
$302.37
price down icon 0.72%
$4.52
price down icon 1.73%
$488.45
price down icon 0.88%
大文字化:     |  ボリューム (24 時間):